News

Event
Partner
Milestone
Partner
2019-10-29

ACT Genomics Works with UC San Diego Team to Predict Immunotherapy Response from Tumor Microenvironment (TME)

ACT Genomics and UC San Diego Moores Cancer Center have launched a study to evaluate gene expressions associated with the tumor microenvironment (TME) in PD-1 treatment outcome prediction for 100 melanoma patients. The study relies on a proprietary chip-b

Place:

Taiwan

Partner
2019-07-29

ACT Genomics Collaborates with AIA Hong Kong to Promote Precision Cancer Medicine!

ACT Genomics is excited to collaborate with AIA Hong Kong to bring ACT Genomics’ leading cancer profiling service to AIA Hong Kong customers.

Place:

Taiwan

Partner
2018-07-06

ACT Genomics signs MOU with Bumrungrad International Hospital to offer services in Thailand

ACT Genomics is pleased to announce that it has signed a memorandum of understanding (MOU) with Bumrungrad International Hospital (BIH) to offer genomic diagnostic services in Thailand.

Place:

Thailand

Partner
2018-07-06

ACT Genomics and Allegiant Regional Care Hospital Announce Partnership in Cebu, Philippines.

ACT Genomics and ARC Hospitals, a new premier hospital group in the Philippines, are collaborating to offer genomic testing services in Cebu, Philippines.

Place:

Philippines

Partner
2017-12-17

ACT Genomics partners with Quark Biosciences to develop tumor micro-environment chip

ACT Genomics announces partnership with Quark Biosciences to develop tumor micro-environment chip (TME Chip) as a universal biomarker for cancer immunotherapy, aiming to increase the response rate by identifying suitable patients with precision.

Place:

Taipei

Partner
2017-11-01

ACT Genomics partners with ASLAN Pharmaceuticals in biomarker exploration for Varlitinib

ACT Genomics officially launched collaboration with ASLAN Pharmaceuticals as the biomarker exploration partner for Varlitinib in the global pivotal trial to investigate Varlitinib as a treatment for gastric cancer, biliary tract cancer, and metastatic col

Place:

Partner
2017-04-18

ACT Genomics Singapore is granted research project collaboration from National University Hospital

ACT Genomics reaches another milestone in cancer research field in Singapore! ACT Genomics Singapore successfully won the opportunity to collaborate with the National University Hospital (NUH) ...

Place:

Singapore

Partner
2017-01-26

ACT Genomics is Collaborating With Ignyta on Phase II STARTRK-2 Trial of Entrectinib

ACT Genomics has entered into a service agreement to screen patients for Ignyta, an oncology biotechnology company, who is enrolling all types of solid tumor patients harboring NTRK1,2,3/ROS1/ALK gene

Place:

USA

Partner

ACT Genomics Works with UC San Diego Team to Predict Immunotherapy Response from Tumor Microenvironment (TME)

ACT Genomics and UC San Diego Moores Cancer Center have launched a study to evaluate gene expressions associated with the tumor microenvironment (TME) in PD-1 treatment outcome prediction for 100 melanoma patients. The study relies on a proprietary chip-b

Place:

Taiwan

Partner

A

A

Place:

A